REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday. RGNX has been the topic of a ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended ...

As the world recognizes Rare Disease Day on Feb. 28, Rockville-based biotechnology company, REGENXBIO is working to change ...

Regenxbio Inc (RGNX)股价已触及52周新低，跌至6.54美元，目前市值为3.3047亿美元，该生物科技公司正面临严峻的市场环境。根据 InvestingPro ...

周二，高盛对Regenxbio Inc. (NASDAQ: RGNX )的投资立场做出重大调整，将该股评级从"买入"下调至"中性"，并将目标价从此前的$38.00大幅下调至$14.00。根据 InvestingPro 数据显示，尽管公司整体财务健康评分为"一般"，但其当前的公允价值表明可能被低估。

ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has ...

REGENXBIO (NASDAQ:RGNX – Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on RegenXBio (RGNX – Research Report) on February 20 and set a price target of ...

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases.

Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...

RegenXBio (RGNX – Research Report) received a Hold rating and price target from Goldman Sachs analyst Paul Choi today. The company’s shares ...